Inunivariate analysis, having a higher Glea-sonscore (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Background:Anti-vascular endothelial growth factor (Anti-VEGF) agents area promising approach to increase theefficacy of treatment for treatment-resistant prostate cancer.Aims:Tocorrelate vascular endothelial growth factor (VEGF) ex-pression andoutcome following radiation therapy in thetreatment of clinically localized prostate cancer.Study Design: Retrospective observational study.Methods:Forty-one patients andclinically localized disease that were treated withradiation therapy were analyzed.
📊
Key Findings & Data:Twenty-four patients wereclassified ashaving low(0to 4 IRS)and17patients wereclassified ashaving high (5 to 8 IRS) VEGF expression.Results:Themedian agewas71years, median follow-up was5.4 years andmedian radiation therapy dosewas70Gy.VEGF expres-sionwascalculated aslowin24patients andhighin17patients.
💡
Conclusion & Impact:Inunivariate analysis, having a higher Glea-sonscore (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Background:Anti-vascular endothelial growth factor (Anti-VEGF) agents area promising approach to increase theefficacy of treatment for treatment-resistant prostate cancer.Aims:Tocorrelate vascular endothelial growth factor (VEGF) ex-pression andoutcome following radiation therapy in thetreatment of clinically localized prostate cancer.Study Design: Retrospective observational study.Methods:Forty-one patients andclinically localized disease that were treated withradiation therapy were analyzed. ForVEGF ex-pression, immunoreactivity scores (IRS) were calculated using per-centscores andintensity scores. Twenty-four patients wereclassified ashaving low(0to 4 IRS)and17patients wereclassified ashaving high (5 to 8 IRS) VEGF expression.Results:Themedian agewas71years, median follow-up was5.4 years andmedian radiation therapy dosewas70Gy.VEGF expres-sionwascalculated aslowin24patients andhighin17patients. Higher VEGF expression wasobserved in6/26 patients with a lowGleason score versus 11/15 patients witha highGleason score (p=0.02). Biochemical failure (BF) wasobserved in2/24patients withlowVEGF expression versus 7/17patients withhighVEGF expression (p=0.01). Inunivariate analysis, having a higher Glea-sonscore (p
🔖
Cite This Article
TEPEOĞLU, M., BORA, H., ERKAL, E. Y., AKMANSU, M. (2022). Role of Vascular Endothelial Growth Factor in Clinically Localized Prostate Cancer Treated with Radiation Therapy. Balkan Medical Journal, Cilt: 31 - Sayı: 1, 43–49. https://ajindex.com/articles/461442
Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066-73. [CrossRef] Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, et al. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002;60:634-9. [CrossRef] Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9. [CrossRef] Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-56. [CrossRef] Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001;61:2413-9.
Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008;9:342-51. [CrossRef] D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74. [CrossRef] Cvetkovic D, Movsas B, Dicker AP, Hanlon AL, Greenberg RE, Chapman JD, et al. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 2001;57:821-5. [CrossRef] Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, et al. Transatlantic Prostate Group. Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 2006;95:1186-94. [CrossRef] Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, Fearn P